Teriparatide

CAS No.: 52232-67-4

Teriparatide Chemical Structure

Molecular formula: C₁₈₁H₂₉₁N₅₅O₅₁S₂

Molecular weight: 4117. 77 g·mol⁻¹

Patent period: —

Dositive specifications: –

Injection : –

Oral tablets: —

Injection: —

Get in touch Download

Products are for laboratory research use only. Not for human use. We do not sell to patients.

Biological Activity

Teriparatide is indicated for the treatment of postmenopausal women with osteoporosis; for the increase of bone mass in men with primary or hypogonadal osteoporosis; and treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.

Chemical Properties

CAS NO.	52232-67-4
FORMULA	C₁₈₁H₂₉₁N₅₅O₅₁S₂
M. WT	4117. 77 g·mol⁻¹
Bioavailability	95%
Metabolism	Liver (nonspecific proteolysis)
STORAGE	—

Online Inquiry

Osteoporosis

Osteoporosis is a bone disease that develops when bone mineral density and bone mass decreases, or when the quality or structure of bone changes. This can lead to a decrease in bone strength that can increase the risk of broken bones (fractures).

Other Drug Peptide More+

Linaclotide new

Linaclotide is a potent and selective guanylate cyclase C agonist; Developed for the treatment of constipation-type irritable bowel syndrome (IBS-C) and chronic constipation.
Thymalfasin

Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide.
Atosiban

Atosiban is a peptide Oxytocin Receptor Inhibitor. Atosiban is a nonapeptide, desamino-oxytocin analogue, and a competitive vasopressin/oxytocin receptor antagonist (VOTra) . Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells and reduced influx of Ca2+ from the extracellular space through voltage-gated channels occur. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua.
Tesamorelin

EGRIFTA is a growth hormone releasing factor (GRF) analogindicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy:
Terlipressin

Terlipressin is a potent vasoconstrictor that acts via V1 receptors on arteriolar smooth muscle cells.

Product Catalog

Teriparatide

GUIZHOU MTPEPTIDES BIOTECHNOLOGY CO., LTD